Business Description
Cue Biopharma Inc
NAICS : 325412
SIC : 2834
ISIN : US22978P1066
Share Class Description:
CUE: Ordinary SharesCompare
Compare
Traded in other countries / regions
CUE.USA1UC.Germany Index Membership
Russell 2000Russell 2000Russell 3000 IPO Date
2018-01-02Description
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune disease with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103 and others.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 3.41 | |||||
| Equity-to-Asset | 0.57 | |||||
| Debt-to-Equity | 0.38 | |||||
| Debt-to-EBITDA | -0.24 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | -10.43 | |||||
| Beneish M-Score | -1.86 | |||||
| WACC vs ROIC | ||||||
Growth Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 2.9 | |||||
| 3-Year EBITDA Growth Rate | 13.8 | |||||
| 3-Year EPS without NRI Growth Rate | 10.8 | |||||
| 3-Year FCF Growth Rate | 8.9 | |||||
| 3-Year Book Growth Rate | -32.9 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 25.48 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 46.7 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 33.49 | |||||
| 9-Day RSI | 39.88 | |||||
| 14-Day RSI | 44.08 | |||||
| 3-1 Month Momentum % | 13.11 | |||||
| 6-1 Month Momentum % | 89.27 | |||||
| 12-1 Month Momentum % | -41.53 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.22 | |||||
| Quick Ratio | 2.22 | |||||
| Cash Ratio | 1.93 | |||||
| Days Sales Outstanding | 74.73 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -15.9 | |||||
| Shareholder Yield % | -18 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -478.79 | |||||
| Net Margin % | -468.02 | |||||
| FCF Margin % | -402.05 | |||||
| ROE % | -142.28 | |||||
| ROA % | -82.16 | |||||
| ROIC % | -234.33 | |||||
| 3-Year ROIIC % | 182.66 | |||||
| ROC (Joel Greenblatt) % | -686.57 | |||||
| ROCE % | -116.91 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 6.38 | |||||
| PB Ratio | 2.91 | |||||
| Price-to-Tangible-Book | 2.92 | |||||
| EV-to-EBIT | -1.26 | |||||
| EV-to-EBITDA | -1.37 | |||||
| EV-to-Revenue | 5.74 | |||||
| EV-to-Forward-Revenue | 6.84 | |||||
| EV-to-FCF | -1.43 | |||||
| Price-to-GF-Value | 0.49 | |||||
| Price-to-Net-Current-Asset-Value | 4.08 | |||||
| Price-to-Net-Cash | 5.57 | |||||
| Earnings Yield (Greenblatt) % | -79.37 | |||||
| FCF Yield % | -49.38 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:CUE
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Cue Biopharma Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 9.532 | ||
| EPS (TTM) ($) | -0.91 | ||
| Beta | 1.74 | ||
| 3-Year Sharpe Ratio | -0.22 | ||
| 3-Year Sortino Ratio | -0.38 | ||
| Volatility % | 135.53 | ||
| 14-Day RSI | 44.08 | ||
| 14-Day ATR ($) | 0.134386 | ||
| 20-Day SMA ($) | 1.354 | ||
| 12-1 Month Momentum % | -41.53 | ||
| 52-Week Range ($) | 0.45 - 2.26 | ||
| Shares Outstanding (Mil) | 63.35 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Cue Biopharma Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Cue Biopharma Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Cue Biopharma Inc Frequently Asked Questions
What is Cue Biopharma Inc(CUE)'s stock price today?
The current price of CUE is $1.23. The 52 week high of CUE is $2.26 and 52 week low is $0.45.
When is next earnings date of Cue Biopharma Inc(CUE)?
The next earnings date of Cue Biopharma Inc(CUE) is 2025-04-08 Est..
Does Cue Biopharma Inc(CUE) pay dividends? If so, how much?
Cue Biopharma Inc(CUE) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers